Goldfinch Bio Email Format
Biotechnology ResearchMassachusetts, United States2-10 Employees
Goldfinch Bio is a small Cambridge, Massachusetts-based biotechnology company focused on kidney diseases. It pursues precision medicine to address the underlying causes of kidney conditions by discovering, developing, and commercializing treatments, guided by a product engine that maps molecular and phenotypic heterogeneity across patient populations. The company maintains a pipeline of novel precision medicine candidates targeting kidney diseases with significant unmet medical need. The firm operates in the biotechnology research industry as a clinical-stage organization translating kidney biology into targeted therapies. In 2026, Bristol Myers Squibb acquired Goldfinch Bio, indicating continued industry interest in its programs.